“On Monday, March 26, at 10 a.m., the House Oversight Committee will hold a hearing to examine the high cost of biotech medicines to our health care system, as well the prospects and need for a pathway that would allow the FDA to approve safe and affordable generic versions of biotech drugs. Witnesses will include representatives of FDA, pharmaceutical manufacturers, scientists, and consumer groups.”